Literature DB >> 7679696

TSG-14, a tumor necrosis factor- and IL-1-inducible protein, is a novel member of the pentaxin family of acute phase proteins.

G W Lee1, T H Lee, J Vilcek.   

Abstract

TNF-stimulated gene (TSG)-14 was originally identified as a TNF-inducible gene in a differentially screened cDNA library derived from TNF-treated normal human FS-4 fibroblasts. Analysis of the TSG-14 cDNA sequence revealed a major open reading frame encoding a protein of 381 amino acids, including a hydrophobic signal peptide sequence. The predicted protein shows 23 to 27% sequence homology to C-reactive protein and serum amyloid P-component, members of the pentaxin family of acute phase proteins. In addition, TSG-14 protein contains a sequence motif common among the pentaxin proteins. The ability of the TSG-14 cDNA to encode a protein of the correct molecular size was confirmed in a cell-free transcription/translation system. In vitro translation in the presence of microsomes confirmed that the protein has a cleavable signal peptide sequence, and that it is glycosylated. TSG-14 mRNA is rapidly elevated from almost undetectable levels in untreated FS-4 cells to high levels in cells treated with TNF or IL-1. A moderate increase in TSG-14 mRNA was observed in FS-4 cells treated with the glucocorticoid dexamethasone. Nuclear run-on analysis indicated that TNF induces the expression of the TSG-14 gene at the transcriptional level, and that de novo protein synthesis is not required for induction of TSG-14 mRNA. Expression of TSG-14 mRNA was also detected after exposure to TNF in vascular endothelial cells; however, little or not expression of TSG-14 message was observed in cell lines derived from malignant tumors. Our data strongly suggest that TSG-14 is a novel member of the pentaxin family of acute phase proteins.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679696

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  77 in total

1.  Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA).

Authors:  M M Luchetti; G Piccinini; A Mantovani; G Peri; C Matteucci; G Pomponio; M Fratini; P Fraticelli; P Sambo; C Di Loreto; A Doni; M Introna; A Gabrielli
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

2.  Correlations between pentraxin 3 or cytokine levels in gingival crevicular fluid and clinical parameters of chronic periodontitis.

Authors:  Yuzo Fujita; Hiroshi Ito; Satoshi Sekino; Yukihiro Numabe
Journal:  Odontology       Date:  2011-09-20       Impact factor: 2.634

Review 3.  Anti-inflammatory actions of serine protease inhibitors containing the Kunitz domain.

Authors:  Hiroshi Shigetomi; Akira Onogi; Hirotaka Kajiwara; Shozo Yoshida; Naoto Furukawa; Shoji Haruta; Yasuhito Tanase; Seiji Kanayama; Taketoshi Noguchi; Yoshihiko Yamada; Hidekazu Oi; Hiroshi Kobayashi
Journal:  Inflamm Res       Date:  2010-05-08       Impact factor: 4.575

4.  From IFN to TNF: a journey into realms of lore.

Authors:  Jan Vilcek
Journal:  Nat Immunol       Date:  2009-06       Impact factor: 25.606

5.  Constitutive expression of pentraxin 3 (PTX3) protein by human amniotic membrane cells leads to formation of the heavy chain (HC)-hyaluronan (HA)-PTX3 complex.

Authors:  Suzhen Zhang; Ying-Ting Zhu; Szu-Yu Chen; Hua He; Scheffer C G Tseng
Journal:  J Biol Chem       Date:  2014-03-20       Impact factor: 5.157

6.  Pentraxin-3 modulates lipopolysaccharide-induced inflammatory response and attenuates liver injury.

Authors:  Luis Perea; Mar Coll; Lucia Sanjurjo; Delia Blaya; Adil El Taghdouini; Daniel Rodrigo-Torres; José Altamirano; Isabel Graupera; Beatriz Aguilar-Bravo; Marta Llopis; Julia Vallverdú; Joan Caballeria; Leo A van Grunsven; Maria-Rosa Sarrias; Pere Ginès; Pau Sancho-Bru
Journal:  Hepatology       Date:  2017-07-18       Impact factor: 17.425

7.  Temporal profiling and pulsed SILAC labeling identify novel secreted proteins during ex vivo osteoblast differentiation of human stromal stem cells.

Authors:  Lars P Kristensen; Li Chen; Maria Overbeck Nielsen; Diyako W Qanie; Irina Kratchmarova; Moustapha Kassem; Jens S Andersen
Journal:  Mol Cell Proteomics       Date:  2012-07-16       Impact factor: 5.911

8.  Increased expression of long pentraxin PTX3 in inflammatory bowel diseases.

Authors:  Shingo Kato; Mitsuko Ochiai; Tomoya Sakurada; Shino Ohno; Kyoko Miyamoto; Mina Sagara; Masataka Ito; Kyoko Takeuchi; Junko Imaki; Kazuro Itoh; Koji Yakabi
Journal:  Dig Dis Sci       Date:  2007-11-08       Impact factor: 3.199

9.  Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH).

Authors:  Masato Yoneda; Takashi Uchiyama; Shingo Kato; Hiroki Endo; Koji Fujita; Kyoko Yoneda; Hironori Mawatari; Hiroshi Iida; Hirokazu Takahashi; Hiroyuki Kirikoshi; Masahiko Inamori; Yuichi Nozaki; Noritoshi Kobayashi; Kensuke Kubota; Satoru Saito; Shiro Maeyama; Mina Sagara; Hiroyuki Aburatani; Tatsuhiko Kodama; Atsushi Nakajima
Journal:  BMC Gastroenterol       Date:  2008-11-14       Impact factor: 3.067

10.  Regulation of pentraxin-3 by antioxidants.

Authors:  A L Hill; D A Lowes; N R Webster; C C Sheth; N A R Gow; H F Galley
Journal:  Br J Anaesth       Date:  2009-10-28       Impact factor: 9.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.